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Abstract
ATAD5, the human ortholog of yeast Elg1, plays a role in PCNA deubiquitination. Since PCNA modification is important to
regulate DNA damage bypass, ATAD5 may be important for suppression of genomic instability in mammals in vivo. To test
this hypothesis, we generated heterozygous (Atad5
+/m) mice that were haploinsuffficient for Atad5. Atad5
+/m mice displayed
high levels of genomic instability in vivo, and Atad5
+/m mouse embryonic fibroblasts (MEFs) exhibited molecular defects in
PCNA deubiquitination in response to DNA damage, as well as DNA damage hypersensitivity and high levels of genomic
instability, apoptosis, and aneuploidy. Importantly, 90% of haploinsufficient Atad5
+/m mice developed tumors, including
sarcomas, carcinomas, and adenocarcinomas, between 11 and 20 months of age. High levels of genomic alterations were
evident in tumors that arose in the Atad5
+/m mice. Consistent with a role for Atad5 in suppressing tumorigenesis, we also
identified somatic mutations of ATAD5 in 4.6% of sporadic human endometrial tumors, including two nonsense mutations
that resulted in loss of proper ATAD5 function. Taken together, our findings indicate that loss-of-function mutations in
mammalian Atad5 are sufficient to cause genomic instability and tumorigenesis.
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Introduction
Chromosomal instability is a common feature of many tumors
[1]. However, the genetic basis of chromosomal instability (CIN)
in human tumorigenesis is poorly understood [2]. In contrast,
genetic screens in S. cerevisiae have identified many genes con-
trolling a variety of processes such as chromosome condensation,
sister-chromatid cohesion, kinetochore structure and function,
centrosome and microtubule formation and dynamics, and cell-
cycle checkpoints [3–5] which, when mutated, lead to CIN. There
is a growing body of evidence starting to emerge to support
the idea that the presence of a CIN phenotype could lead to
mammalian tumorigenesis [6–11]. Moreover, based on the
observation that there are evolutionarily conserved synthetic lethal
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been proposed that identifying CIN genes that are disrupted in
human cancer could lead to the design of rational therapeutics
[5,12,13].
The yeast ELG1 gene was originally identified in screens for
suppressors of CIN and telomere maintenance proteins [3,4,
14,15,16,17]. Recently, we demonstrated that human ATAD5
(hELG1), responds to a wide range of DNA damaging agents, and
that reduced expression of ATAD5 in cell lines leads to sensitivity
to DNA damaging agents, and high levels of genomic instability
[18]. In addition, we found that human ATAD5, together with
a deubiquitinating enzyme complex, USP1-UAF1, functions to
reduce the level of ubiquitinated PCNA on chromatin [19].
Defects in the regulation of PCNA ubiqutination result in defi-
ciency in the post-replication repair pathways. Although the
importance of the post-replication pathway in the suppression of
tumorigenesis has been highlighted by the discovery that germline
mutations in the POLH gene, which encodes a polymerase func-
tioning in a post-replication repair pathway, are responsible for the
variant form of Xeroderma Pigmentosum, a skin cancer-prone
syndrome [20,21], it has not yet been demonstrated whether the
regulation of post-replication pathways by PCNA ubiquitination is
important for tumor suppression.
Because reduced expression of ATAD5 is associated with high
levels of genomic instability in vitro [19], we hypothesized that
reduced expression of mouse Atad5 would also lead to genomic
instability in vivo. Here we demonstrate that mice heterozygous for
Atad5 display high levels of genomic instability in vivo and that
.90% of Atad5
+/m mice develop a variety of spontaneous tumors.
Mouse embryonic fibroblasts (MEFs) derived from the Atad5
heterozygous mice were highly sensitive to DNA damaging agents,
demonstrating high levels of aneuploidy and genomic instability in
response to DNA damage. We further show that somatic, loss-of-
function mutations in ATAD5 are present in a subset of primary
human endometrial cancers. Taken together, our findings provide
the first evidence to indicate that mammalian Atad5 suppresses
genomic instability and tumorigenesis.
Results
Characterization of the Atad5 Mutant Allele in the
RRF055 ES Cell Line
To investigate whether Atad5 is critical for the maintenance of
genomic stability in vivo, we generated a mouse model using a 129/
Sv background embryonic stem (ES) cell line, RRF055 from
Baygenomics (http://baygenomics.ucsf.edu). RRF055 has a ret-
roviral insertion between exons 18 and 19 of the Atad5 gene in
mouse chromosome 11qB5 (79,902,914–79,949,293; Figure 1A).
The retroviral insertion in the ES cells was confirmed by
sequencing a PCR product amplified using a primer set specific
to sequences at the intron following exon 18 of Atad5 gene and
the LacZ gene (Figure 1A and 1B). Although we could recover
Atad5
m/m embryos at embryonic day 3.5, no Atad5
m/m mice were
born after intercrossing Atad5
m/+ mice (Figure 1B). There was no
significant difference in the level of mRNA containing exons 4 and
5 between Atad5
+/m and wild type MEFs (Figure 1C). In contrast,
the expression levels of mRNA containing exons 18, 19, and 20
were reduced by half in the Atad5
+/m MEFs compared to wild type
MEFs. Consistent with 50% decrease in full length Atad5 mRNA,
the level of full length Atad5 protein was also reduced by at least
half in Atad5
+/m MEFs compared to wild type MEFs (Figure 1D).
For Atad5, the RefSeq transcript is the only transcript that
represents a full-length cDNA. Although there are several shorter,
putative transcripts included in the UCSC, Ensembl, and NCBI
genome browsers these are based on large-scale cDNA sequencing
projects and are not sufficiently well annotated to be included in
the Consensus CDC project, which is a collaborative effort to
identify a core set of protein coding regions.
Mouse Atad5 is located close to the Nf1 tumor suppressor gene.
To exclude the possibility that the retroviral insertion affected
the expression of Nf1, the mRNA level of Nf1 was measured in
Atad5
+/m MEFs. There was no significant difference in the mRNA
expression of Nf1 in Atad5
+/m MEFs compared to wild type MEFs
indicating that the retroviral insertion only reduced the level of
Atad5 (Figure 1C).
To determine whether the fused mRNA of Atad5 and LacZ
generated a hybrid protein, we analyzed b galactosidase expres-
sion in Atad5
+/m MEFs either by immunohistochemistry or by
western blotting of whole cell extracts with b-galactosidase or
Atad5 antibodies. No protein expression was observed (Figure 1E
and 1G) although RT-PCR analysis with a primer for Atad5 exon
18 and another primer for LacZ demonstrated expression of a
fused mRNA that was in-frame as determined by sequencing the
RT-PCR product (Figure 1F). The human ATAD5 protein is
stabilized and forms foci in the nuclei of cultured cells in response
to DNA damage [18]. Therefore, we reasoned that if the b-
galactosidase-fused Atad5 were expressed, it would form foci and
be more readily detectable in the presence of DNA damage. After
one hour of 0.01% methyl methane sulfonate (MMS) treatment,
we did not detect any foci formation of b-galactosidase-fused
Atad5 (Figure 1H). We conclude that an mRNA encoding the N-
terminal 1347 amino acids of Atad5 fused with LacZ is transcribed,
but the fused protein is not stable.
Atad5 Deficiency Causes Genomic Instability
To investigate whether Atad5 suppresses genomic instability in
vivo, we used two different assays. In the first assay, we compared
the frequency of micronuclei formation in peripheral blood
reticulocytes following ionizing radiation treatment of wild type
and Atad5
+/m mice. Unlike anucleated RETs that are produced
during normal differentiation, micronucleated reticulocytes (MN-
RETs) have a micronucleus that is produced by lagging or
fragmented chromosomes resulting from genomic instability [22].
Therefore, the frequency of MN-RETs provides a measure of
genomic instability. In response to 0.7 Gy c-irradiation, the
frequency of MN-RETs in Atad5
+/m mice increased 3.3-fold after
48 hours compared to the 1.4-fold increase observed in wild type
mice (Figure 2A). The increase in MN-RETs observed in Atad5
+/m
mice was about half of the 7.3-fold increase observed in severe
Author Summary
Genomic instability is a hallmark of tumorigenesis,
suggesting that mutations in genes suppressing genomic
instability contribute to this phenotype. In this study, we
demonstrate for the first time that haploinsufficiency for
Atad5, a protein that is important in stabilizing stalled DNA
replication forks by regulating PCNA ubiquitination during
DNA damage bypass, predisposes .90% of mice to
tumorigenesis in multiple organs. In heterozygous Atad5
mice, both somatic cells and the spontaneous tumors
showed high levels of genomic instability. In a subset of
sporadic human endometrial tumors, we identified het-
erozygous loss-of-function somatic mutations in the
ATAD5 gene, consistent with the role of mouse Atad5 in
suppressing tumorigenesis. Collectively, our findings
suggest that ATAD5 may be a novel tumor suppressor
gene.
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PLoS Genetics | www.plosgenetics.org 2 August 2011 | Volume 7 | Issue 8 | e1002245Figure 1. Disruption of the mouse Atad5 gene by insertional mutagenesis. (A) Schematic diagram of wild type and mutant Atad5 loci. Exons
17–19 are indicated as solid boxes. LacZ and NEO indicate the location of the cassette that disrupted Atad5 gene expression by insertional
mutagenesis. Arrows and numbers between arrows indicate the locations of primers used for genotyping and expected sizes of PCR products,
respectively. PCR with gray and black primer that can bind wild type locus generates 542 bp PCR products from wild type loci but not in mutant
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DNA-dependent protein kinase catalytic subunit, a major DNA
double-strand break repair enzyme. We conclude that the hetero-
zygous mutation of Atad5 causes genomic instability in vivo fol-
lowing exposure to c-irradiation.
In a second assay, we measured genomic instability in cultured
cells. Atad5
+/m mouse embryo fibroblasts (MEFs) exhibited a high
level of genomic instability in response to MMS (Figure 2B).
Following 0.01% MMS treatment, 72% of Atad5
+/m MEFs had
more than 10 chromatid breaks compared to 18% of wild type
MEFs. Furthermore, untreated Atad5
+/m MEFs displayed a
significantly higher level of spontaneous aneuploidy compared to
Atad5
+/+ mice (Figure 2C). In addition, Atad5
+/m MEFs increased
sensitivity to MMS treatment compared to wild type MEFs
(Figure 2D).
To investigate whether the genomic instability observed in
Atad5
+/m mice is evolutionarily conserved, we constructed ATAD5-
deficient heterozygous DT40 cells by targeted knockout of one
allele of chATAD5, and monitored their sensitivity to DNA
damage. In two individual heterozygous ATAD5-deficient chicken
DT40 clones, DNA damaging agent sensitivity was observed
(Figure S1). In addition, ATAD5-deficient heterozygous DT40 cells
exhibited higher levels of chromosomal instabilities in response to
ionizing radiation than wild type DT40 cells (Figure S1).
Collectively, these findings indicate that heterozygous mutation
of the Atad5 gene in mouse and chicken cells causes a defect in the
DNA damage response, which is consistent with the known role of
yeast Elg1 and human ATAD5 in suppressing genomic instability
[18,23,24,25].
The high levels of genomic instability and sensitivity to DNA
damaging agents that we observed in Atad5
+/m MEFs (Figure 2)
suggested that Atad5 haploinsufficiency causes defects in DNA
repair. To test this hypothesis, DNA from wild type and Atad5
+/m
MEFs were analyzed by pulsed-field gel electrophoresis after
0.01% MMS treatment and a 16 hour recovery period. Atad5
+/m
MEFs displayed smaller DNA fragments following 0.01% MMS
treatment compared to wild type MEFs (Figure 3A), suggesting a
defect in DNA repair in Atad5
+/m MEFs.
DNA repair deficiency generates spontaneous DNA damage.
Consistent with this paradigm, after 25 passages in culture without
treatment by DNA damaging agents, Atad5
+/m MEFs had a large
population of cells with spontaneous Rad51 foci, reflecting the
accumulation of DNA damage and possibly hyper-recombination
phenotype in cells (Figure 3B and 3C). Although there was an
increase in Rad51 foci formation in Atad5
+/m MEFs, we did not
observe any significant increase in the sister chromatid exchange
rate in Atad5
+/m MEFs compared to wild type MEFs (Figure 3D).
To independently investigate the accumulation of spontaneous
DNA damage in Atad5
+/m MEFs, H2AX phosphorylation (c-
H2AX) was monitored in wild type and Atad5
+/m MEFs after 25
passages in culture. The frequency of cells exhibiting c-H2AX foci
was greater in Atad5
+/m MEFs than wild type MEFs (Figure 3E and
3F).
Approximately 10% of Atad5
+/m MEFs showed pan nuclear c-
H2AX staining, which is frequently observed in cells undergoing
apoptosis (Figure 3E and 3F). To determine whether Atad5
+/m
MEFs undergo apoptosis, the DNA content of wild type and
Atad5
+/m MEFswas analyzed byFACS at passage 4 and passage 25.
Although there was no clear difference in wild type and Atad5
+/m
MEFs at passage 4, Atad5
+/m MEFs but not wild type MEFs
underwent apoptosis at passage 25 (Figure 3G–3J). To understand
the molecular defects that cause DNA repair deficiency in Atad5
+/m
MEFs, PCNA ubiquitination was investigated. PCNA ubiquitina-
tion was increased more in response to MMS in Atad5
+/m MEFs
compared to wild type MEFs (Figure S2). However, it is important
to point out that we did not observe a similar increase of PCNA
ubiquitination in ATAD5 heterozygous chicken DT40 cells. Taken
together, these data demonstrate that Atad5 haploinsufficiency
causes defects in DNA repair, which results in the accumulation of
spontaneous DNA damage that triggers aneuploidy and apoptosis
and is associated with an inability to reduce PCNA ubiquitination
in the nucleus.
Atad5
+/m Mice Develop a Wide Spectrum of Spontaneous
Tumors That Have High Levels of Genomic Instability
To investigate whether the genomic instability found in the
Atad5
+/m mice leads to tumorigenesis, we monitored a cohort of 42
mice (22 Atad5
+/m mice and 20 wild type age matched controls)
with a normal diet over time. All 22 Atad5
+/m mice either died or
had to be sacrificed due to ill-health between 11 and 20 months of
age whereas all of the wild type mice survived beyond 20 months
(p value,0.001) (Figure 4A). Twenty of 22 (90.9%) Atad5
+/m mice
developed tumors compared to 4 of 20 (20%) wild type mice
(p value,0.001) (Figure 4A and 4B). Tumors that developed in
wild type mice were lung adenomas, which appeared after 24
months. In contrast, necropsy analyses revealed that Atad5
+/m mice
developed a variety of tumors in many tissues and cell types with a
high incidence of adenocarcinomas and sarcomas (Figure 4B and
Table 1). The predominance of adenocarcinomas and sarcomas
observed in Atad5
+/m mice is in stark contrast to the range of
tumors observed in the 129/Sv strain used in this study. Wild type
129/Sv mice develop tumors spontaneously in 7% of male mice
with no prevalence of a specific type [26]; there have been no
reports of wild type 129/Sv strain mice developing adenocarci-
nomas and sarcomas at a high frequency.
Because ATAD5 has been suggested to suppress genomic
instability in yeast and human cells [4,18,24], we hypothesized
that the tumors that arose in the Atad5
+/m mice might be associated
with high levels of genomic instability. We used array-comparative
genome hybridization to determine the genomic copy number
profiles of 2 adenomas and 2 sarcomas from the Atad5
+/m mice.
This revealed numerous copy number variations (CNVs) affecting
locus due to the inserted LacZ-NEO cassette. In contrast, PCR with gray and another black primer that can bind LacZ sequence generates 900 bp PCR
product only from mutant locus. (B) PCR based genotyping of DNAs isolated from mouse embryos at day 3.5 p.c. Wild type and mutant alleles of
Atad5 are represented by + and m, respectively. 1
st and 2
nd lanes in each sample shows PCR products generated from wild type locus (542 bp) and
mutant locus (900 bp) explained in the legend A. (C) RT-PCR analysis of Atad5 mRNA levels in wild type and Atad5
+/m MEFs. The exons to which each
Atad5 primers bind are indicated on the x-axis. (D) Western blot analysis of Atad5 in wild type MEFs and Atad5
+/m MEFs. (E) b galactosidase expression
in wild type (Atad5
+/+; negative control), Atad5
+/m MEF cells, and HEK 293T cells transiently transfected with a plasmid expressing b-galactosidase
(positive control) were examined by immunostaining with a b-galactosidase antibody. (F) The fused Atad5-LacZ transcript was confirmed by RT-PCR.
M stands for molecular marker. A 210 bp RT-PCR product only from Atad5
+/m cDNA MEF cells was detected. (G) b galactosidase expression in wild
type (Atad5
+/+; negative control), Atad5
+/m MEF cells, and HEK 293T cells transiently transfected with a plasmid expressing b-galactosidase (positive
control) were determined by Western blot analysis. (H) Atad5- b-galactosidase fusion protein was not detected in the Atad5
+/m MEF cells even after
12 hours recovery from 0.01% MMS treatment for one hour by immunostaining with a b-galactosidase antibody. Top and bottom panels are images
of b-galactosidase antibody staining only and merged with DAPI, respectively.
doi:10.1371/journal.pgen.1002245.g001
Cancer Predisposition by Atad5 Mutation
PLoS Genetics | www.plosgenetics.org 4 August 2011 | Volume 7 | Issue 8 | e1002245almost all chromosomes (Figure 4C and Table S1), indicating that
the tumors that arose in Atad5
+/m mice had enhanced genomic
instability. Furthermore, several genomic regions were gained or
lost in multiple tumors.
We next compared the gene expression profiles of one
adenocarcinoma and one sarcoma from Atad5
+/m mice with those
of their surrounding tissues, by microarray analysis. In total, there
was a 2-fold or greater change in the expression of 584 genes,
including 198 cancer-related genes (103 up-regulated and 95
down-regulated), in both tumors compared to the surrounding
tissues. We selected a number of genes that were dysregulated in
tumors and validated the different levels of expression by qRT
PCR (Figure S3B and S3C). When the genome-wide CNVs and
gene expression profiles of tumors from the Atad5
+/m mice were
compared, there was a high degree of positive correlation between
them; 143 of 584 genes that were up- or down-regulated in tumors
appeared to be due to CNVs (Table S3).
To determine whether a specific pathway(s) was activated or
suppressed in tumors, the microarray datasets were analyzed with
the Ingenuity Pathway Analysis software (Figure 4D, Figure S3,
and Table S2). The expression of genes in the TGF-b signaling
network was significantly up-regulated in both tumors (Figure 4D).
Figure 2. The heterozygous Atad5
+/m mutation causes genomic instability in vivo and in MEFs. (A) Atad5
+/m mice exhibited an increase in
IR-induced MN-RETs. Wild type (Atad5
+/+) and SCID mice were treated with IR and their peripheral blood cells were analyzed in the same manner for
comparison. CD71 and propidium iodide (PI) were used to detect RET cells and micronuclei, respectively. Fold induction after IR irradiation in each
mouse with a different genotype normalized to MN-RET from unirradiated mice is presented in the graph. Five wild type, five Atad5
+/m, and two SCID
mice were analyzed. (B) MEFs derived from the Atad5
+/m mice produced more chromatid breaks than wild type MEFs in response to MMS treatment.
Percentages of metaphases having noted number of breaks are presented as graphs. Noticeable chromatid breaks per cell were quantified for 50
metaphases from both wild type and the Atad5
+/m MEFs. (C) MEFs derived from the Atad5
+/m mice have a high level of aneuploidy. (D) Survival of wild
type and the Atad5
+/m MEFs following MMS treatment is displayed as the percentage of viable cells relative to untreated cells. P-values were
calculated or each data point as follows, 0.00125% MMS (p=0.05); 0.0025% MMS (p=0.002), 0.005% MMS (p=0.005), 0.0075% MMS (p=0.09); and
0.01% MMS (p=0.03), respectively.
doi:10.1371/journal.pgen.1002245.g002
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+/m
mice was associated with the activation of TGF-b signaling.
Whether this finding reflects the progression of tumorigenesis
or the mechanism of tumor initiation associated with Atad5
haploinsufficiency has not been determined.
Human ATAD5 Is Somatically Mutated in Primary
Endometrial Cancers
The high incidence of cancer in the Atad5
+/m mice, led us to
hypothesize that somatic mutations of ATAD5 might be associated
with human cancers. To test this hypothesis we searched for
somatic ATAD5 mutations among a series of sporadic human
endometrial tumors. We focused on endometrial cancer because
aneuploidy, a form of CIN, is frequently observed in non-endo-
metrioid endometrial cancers (NEECs) and occurs at a lower
frequency in endometrioid endometrial cancers (EECs) [27]. We
resequenced all coding exons of ATAD5 from 108 primary
endometrial tumors, consisting of 66 NEECs and 42 EECs.
Somatic mutations were distinguished from germline polymor-
phisms by resequencing the variant position from matched normal
DNAs.
Overall, we identified 11 somatic mutations in the ATAD5 gene
in 4.6% (5 of 108) of endometrial tumors (Table 2). The frequency
of somatic ATAD5 mutations was higher among NEECs (6.0%, 4
Figure 3. MEFs derived from the Atad5
+/m mice are defective in DNA repair, display a hyper-recombination phenotype, and are
apoptosis-prone. (A) Atad5
+/m MEFs are defective in DNA repair. Broken DNAs after 0.01% MMS treatment were visualized by pulse field gel
electrophoresis. (B, C) Atad5
+/m MEFs display high levels of spontaneous Rad51 foci in the nucleus. B and C show, respectively, an actual image and a
graphic presentation of the number of Rad51 foci in the nucleus of each cell type. (D) Atad5
+/m MEFs display similar rates of sister chromatid
exchange rate compared to wild type MEFs. (E, F) Atad5
+/m MEFs display high level of cH2AX foci in the nucleus. An actual image (E) and a graphic
presentation (F) of the number of cells having different types of cH2AX foci in the nucleus from each cell type are shown. (G, H, I, J) Atad5
+/m MEFs
undergo apoptosis at the 25
th passage. FACS analysis of wild type (G, H) and Atad5
+/m MEFs (I, J) from the 4
th passage (G, I) and the 25
th passage (H, J)
were performed based on their DNA contents. Bars in images for Atad5
+/+ and Atad5
+/m (B and E) indicate 20 mm and 10 mm, respectively.
doi:10.1371/journal.pgen.1002245.g003
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+/m mice are tumor-prone. (A) Kaplan-Meier survival graph of wild type (Atad5
+/+; n=20) and the Atad5
+/m mice (n=22). (B)
Representative H&E stained sections of tumors that arose in the Atad5
+/m mice; (I) Harderian gland adenoma, (II) hemangioma, (III) lung bronchiolar
adenoma, (IV) thymoma, and (V) sarcoma from bone marrow. The panel on the right is a two-fold magnification of panel on the left. (C) Frequency of
genomic copy number gains and losses among four tumors from the Atad5
+/m mice, plotted as a function of genome location with all chromosomes
starting from 1pter (left) to X (right). Vertical lines indicate chromosome boundaries. Positive and negative values indicate the number of tumors that
showed copy number gains (+) and losses (2), respectively. (D) The pathway activated in two tumors from the Atad5
+/m mice analyzed by microarray.
Red and green colors represent the activation and inactivation in tumors, respectively.
doi:10.1371/journal.pgen.1002245.g004
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reach statistical significance (P=0.48, Fisher’s exact test of
significance). The observed 10:1 ratio of nonsynonymous:synon-
ymous (NS:S) ATAD5 mutations was 5-fold higher than an
expected 2:1 ratio in the absence of selection. All of the somatic
ATAD5 mutations occurred exclusively at cytosine or guanine
residues, and two tumors had multiple mutations. Taken together,
these observations raise the possibility that some of these tumors
may have an underlying a hypermutable phenotype. Two ATAD5
mutations were nonsense mutations predicted to cause premature
protein truncation (Figure 5A). One of the nonsense mutations
(ATAD5-R1414X) occurred in an almost equivalent position to
the insertion mutation within the Atad5 tumor-prone mouse
described here.
Somatic Mutations of Human ATAD5 Result in
Haploinsufficiency and Cause Defects in ATAD5 Function
To test whether the somatic ATAD5 mutations we observed in
human endometrial tumors encode loss-of function proteins, we
compared the functional properties of wild type and mutant
(P91H, P1516T, S1589C, E723X, and R1414X) forms of
ATAD5. These five mutants were chosen for analysis because
they occurred in a mutually exclusive fashion in endometrial
tumors. We analyzed the cellular distribution and stability of the
ATAD5 proteins by transiently transfecting human embryonic
kidney (HEK) 293T cells with Flag-tagged wild type or mutant
ATAD5 constructs. Wild type ATAD5 protein as well as the P91H,
P1516T, S1589C, and R1414X mutant proteins were found
exclusively in the chromatin-bound fraction (Figure 5B). Within
the chromatin-bound fraction, the levels of the ATAD5-P91H
mutant protein were comparable to that of wild type ATAD5
whereas the protein levels of the ATAD5-P1516T and ATAD5-
S1589C mutants were slightly lower than the wild type protein
and the level of the ATAD5-E723X protein was greater than that
of the wild type protein (Figure 5B). The ATAD5-E723X trun-
cated mutant protein was detected in both the soluble fraction and
the chromatin-bound fraction of transfected cells (Figure 5B)
suggesting that the ATAD5-E723X truncation mutant has
impaired chromatin retention. The ATAD5-R1414X truncated
protein was undetectable either in the chromatin-bound or the
soluble fractions of transfected cells (Figure 5B) despite the
observation that the ATAD5-R1414X transcript was expressed at
comparable levels to that of the wild type transcript. This is
consistent with our finding that the mouse model used in this study
makes a transcript encoding the N-terminal 1347 amino acids of
Atad5 fused with LacZ but fails to produce a stable protein
Table 1. Various spectra of tumors were observed in
heterozygous Atad5 mice.
Age "(months) Sex Tumor Type Organ
11 F Sarcoma Skeletal muscles
14 F Sarcoma Uterus
11 F Granulosa Cell Tumor Ovary
14 F Granulosa Cell Tumor Ovary
13 F Spindle Cell Tumor Small intestine/Stomach
17 F Adenocarcinoma Lung
18 F Adenocarcinoma Harderian glands
20 F Adenocarcinoma Harderian glands
14 M Carcinoma Lung
14 M Adenocarcinoma Harderian glands
15 M Sarcoma Peripheral nerve
15 M Lymphoma Lymph/Lung/Liver
15 M Adenocarcinoma Harderian glands
16 M Sarcoma Tail
16 M Sarcoma Hindlimb
16 M Adenocarcinoma Harderian glands
16 M Adenocarcinoma Harderian glands/Lung
17 M Thymoma Thymus
17 M Hemangiosarcoma Subcutis
18 M Adenocarcinoma Liver
Two Atad5
+/m mice that did not develop tumors had abscesses and died from
apparent unresolved infections.
"Age at death or sacrifice due to ill-health.
doi:10.1371/journal.pgen.1002245.t001
Table 2. Somatic mutations of ATAD5 were identified in primary human endometrial tumors.
Case no.{
Tumor
subtype
Nucleotide
change
Amino acid
change
Mutation
type
Predicted effect of missense mutations
on protein function
By SIFT By PolyPhen
T3 NEEC c.G905T S302I Missense Tolerated Probably damaging
T3 NEEC c.C1169A A390D Missense Tolerated Probably damaging
T3 NEEC c.G2167T E723X Nonsense - -
T3 NEEC c.G4380A E1460E Synonymous - -
T113 NEEC c.G892A E298K Missense Tolerated Benign
T113 NEEC c.G1913T S638I Missense Tolerated Possibly damaging
T113 NEEC c.C4546A P1516T Missense Tolerated Probably damaging
T113 NEEC c.C4143A D1381E Missense Tolerated Probably damaging
T51 NEEC c.C4240T R1414X Nonsense - -
T62 NEEC c.C4766G S1589C Missense Tolerated Probably damaging
T88 EEC c.C272A P91H Missense Tolerated Benign
{Case no T3 is also known as OM-1323.
doi:10.1371/journal.pgen.1002245.t002
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predisposition in our mouse model, we sought to determine
whether the wild type ATAD5 allele is expressed in the human
endometrial tumor (T51) with the ATAD5-R1414X mutation. By
sequencing RT-PCR products generated from purified popula-
tions of tumor cells obtained by laser capture microdissection, we
observed expression of both the wild type and ATAD5-R1414X
alleles (Figure S4). We conclude that the truncated ATAD5-
R1414X mutant protein is unstable and that it may contribute to
endometrial cancer by a haploinsufficient mechanism.
ATAD5 forms an RFC-like complex by binding to RFC4, an
invariant subunit of both RFC and RFC-like complexes in
mammalian cells [17]. Immunoprecipitation of RFC4 from
transiently transfected HEK 293T cells, followed by immunoblot-
ting with an anti-Flag antibody, demonstrated that the ATAD5-
E723X truncation mutant had a greatly reduced ability to bind to
RFC4 (Figure 5C). This observation indicates that the ATAD5-
E723X mutant has an impaired ability to form an intact ATAD5-
RFC complex. This is consistent with previous reports that the C-
terminal region of yeast Elg1p is essential for complex formation
with other RFC subunits [28]. We conclude that the presence of
the ATAD5-E723X truncated protein in both the soluble and
chromatin bound fractions of the cell (Figure 5B), may be the
result of a defect in the ability to form an intact ATAD5-RFC
complex. Despite the low levels of the ATAD5-R1414X truncated
protein present in the chromatin-bound fraction, this mutant
Figure 5. Somatic mutations of ATAD5 in primary endometrial tumors exhibit functional defects in vitro. (A) Schematic representation of
the ATAD5 protein showing positions of somatic mutations (arrows) relative to the AAA-ATPase domain. Truncating (boxed), missense (black) and
synonymous (gray) mutations are distinguished. Amino acids are numbered. (B) The ATAD5-R1414X mutant is associated with reduced protein levels.
HEK 293T cells were transfected with constructs expressing wild type (WT) ATAD5 or mutant ATAD5. Soluble fractions, which include cytoplasmic and
nucleoplasmic proteins, and chromatin-bound fractions were separated by SDS-PAGE after 48 h. Relative expression of wild type or mutant ATAD5
was determined by Western blotting with anti-FLAG-antibody. Histone H3 and tubulin were used as loading controls for chromatin-bound and
soluble fractions respectively. Total RNAs, extracted from cells used in the Western blot analysis, served as templates for RT-PCR. ATAD5 mRNA
expression levels determined by quantitative RT-PCR, were normalized to b-actin expression levels and are represented as a relative value compared
to that of vector transfectants. (C) The ATAD5-E723X mutant protein does not interact with RFC4. Chromatin-bound fractions from HEK 293T cells
transfected with constructs expressing wild type or mutant ATAD5 were immunoprecipitated (IP) with anti-RFC4 antibody or IgG control antibody,
and subjected to Western blot analysis.
doi:10.1371/journal.pgen.1002245.g005
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levels of the ATAD5-R1414X protein and the reduced binding of
the ATAD5-E723X protein to RFC4 are consistent with a loss of
ATAD5 function. Although the three missense mutants interacted
with RFC4, it is possible that they might affect the function of the
assembled protein complex by other mechanisms not tested here;
alternatively, these mutations might be so-called ‘‘passenger’’
mutations that have no effect on ATAD5 function.
Discussion
There is an emerging consensus that mutations in chromosomal
instability genes contribute to many kinds of malignancy [29]. For
example, previous studies of endometrial carcinomas have un-
covered somatic alterations of a number of genes implicated in the
maintenance of genomic integrity including somatic mutations in
CDC4/FBXW7, and p53, and amplification or altered expression
of STK15, BUB1, CCNB2, and CCNE [30–33]. In this report we
have demonstrated the first somatic ATAD5 mutations in human
cancer through a resequencing analysis of primary endometrial
carcinomas. The frequency of somatic ATAD5 mutations was
somewhat higher among NEECs than EECs. NEECs are the most
clinically aggressive subtype of endometrial cancer that, as a
group, exhibit aneuploidy, a form of chromosomal instability,
much more frequently than EECs do [27]. Although ATAD5 was
mutated at low frequency in endometrial carcinomas, this is not
unexpected in light of recent studies of whole exomes of breast,
colorectal and pancreatic cancers [34–36]. Those studies revealed
that most somatically mutated genes are mutated at low frequency
but that many infrequently mutated genes impinge on a smaller
number of discrete biological processes and biochemical pathways
resulting in a significant overall contribution to tumorigenesis. In
this regard, it will be interesting, in future studies, to determine the
extent to which the ATAD5 pathway is disrupted in sporadic
endometrial cancer.
The microarray analysis and quantitative PCR of mouse tumor
samples showed that the wild type allele of Atad5 was retained and
was expressed normally. In addition, human endometrial tumors
carrying ATAD5-R1414X mutation expressed both the wild type
and mutant alleles. These data are consistent with a mechanism by
which haploinsufficiency of ATAD5 causes genomic instability
leading to malignant transformation.
We have also recently reported increased CIN in a human cell
line expressing reduced levels of ATAD5 following siRNA
silencing [18]. The reduced expression of ATAD5 in human cells
resulted in a spontaneous hyper-recombination phenotype [19].
Finally, primary Atad5
+/m fibroblasts had high levels of aneuploidy
and other visible genome damage in culture, even in the absence
of DNA damaging agents and tumors from Atad5
+/m mice exhi-
bited a large number of spontaneous genomic copy number
alterations. It is possible that the high level of spontaneous
genomic damage might be due to defects in the removal of
ubiquitin from PCNA by ATAD5 together with USP1-UAF1 after
DNA damage bypass [19]. In this model the persistent presence of
ubiquitinated PCNA on DNA could retain translesion synthesis
DNA polymerases in DNA replication forks. Due to their low
processivity, DNA replication forks that have prolonged transle-
sion synthesis DNA polymerases could collapse and abnormal
recombination might enact to create a high level of genomic
instability and tumors in the Atad5
+/m mouse. Consistent with this
possibility, we observed higher levels of PCNA ubiquitination in
response to MMS in Atad5
+/m MEFs compared to wild type MEFs.
Interestingly, the Atad5
+/m MEFs displayed high levels of
spontaneous Rad51 foci that might lead to a high level of
recombination although there was no significant induction of sister
chromatid exchange rate. However, it is worth noting that recent
studies have shown that the Usp1 knock-out mice, and the PCNA-
K164R knock-in mice both have milder phenotypes [37,38]
compared to Atad5
+/m mice. Therefore we cannot exclude the
possibility that tumorigenesis in the Atad5
+/m mice might not be
due to the dysregulation of PCNA ubiquitination, but instead
might result from other defects caused by Atad5 haploinsuffi-
ciency. For example, it is possible that haploinsufficiency for Atad5
might affect DNA replication especially in Okazaki fragment
maturation during lagging strand synthesis because it has been
observed that yeast Elg1 interacts with Rad27, the yeast homolog
of the FEN1 flap endonuclease, which specifically removes RNA
primers, during lagging strand maturation [17].
Late passage Atad5
+/m MEFs undergo apoptosis in the absence
of DNA damaging agents. This is somewhat paradoxical because
tumorigenesis is frequently associated with impaired apoptosis.
Nonetheless, there are several examples of tumorigenesis requiring
apoptosis [39,40]. We speculate that tumors that arise in Atad5
+/m
mice might be result from high levels of cell turnover associated
with the increased attrition of stem cells that presumably
accompanies high levels of spontaneous DNA damage. Therefore,
there was increased risk of transformation. Alternatively, it is
possible that the DNA damage that occurs in Atad5
+/m cells might
lead to the accumulation of additional mutations that render
Atad5
+/m cells resistant to apoptosis, thus accounting for the 11-
month latency period before the appearance of tumors.
In conclusion, our study provides the first evidence that loss of
Atad5/ATAD5 function is associated with tumorigenesis. Our
findings warrant future investigations to explore the role of ATAD5
in other human cancers. As concerted efforts to systematically
sequence entire tumor exomes and genomes move forward
rapidly, we predict that a wider spectrum of sporadic human
tumors will harbor acquired somatic ATAD5 mutations. Further-
more, given our observation that haploinsufficiency for Atad5 in
mice predisposes to tumorigenesis, it will also be important to
determine whether germline variants of ATAD5 confer increased
risk for cancer. Notably, there are studies suggesting a higher
cancer incidence in approximately 5 to 10% of Neurofibromatosis
type 1 patients who have a micro-deletion that includes NF1,
ATAD5, and several other genes [41,42]. The high incidence of
tumors in the heterozygous Atad5
+/m mice in this study raises the
possibility that the tumors in NF1 microdeletion patients might
arise as a result of a synergistic effect mediated by the co-deletion
of ATAD5.
Materials and Methods
Generation of Atad5
+/m Mice
Mice used in this study were derived from the ES cell line (ID:
RRF055, 129/Sv background). Chimeric male mouse generated
from the ES cell injected C57BL/6 blastocytes were transferred
into pseudopregrant CD1 female recipients. All mice works were
conducted under in compliance with federal regulations and
guidelines. All mice work in this study was approved by the
NHGRI Animal Care and Use Committee (NIH animal study
proposal: G-05-2, KM as a PI).
MN-RET Assay
We followed the method described previously [22]. Briefly, six-
week old male mice were exposed to 0.7 Gy of c-ray irradiation
from a
137Cs source. Normochromatic erythrocytes (NCEs) and
reticulocytes (RETs) in erythrocytes were distinguished by their
negative and positive expressions of CD71 in cell surface,
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nucleic acid binding agent propidium iodide. At least 10,000
RETs and 500,000 NCEs were analyzed in each blood sample.
Clinical Specimens
Anonymized primary endometrial tumor tissues (n=102) and
matched histologically normal tissues were obtained from the
Cooperative Human Tissue Network, or from the Biosample
Repository at Fox Chase Cancer Center, Philadelphia PA. Six
cases of matched tumor and normal DNAs were purchased from
Oncomatrix. All primary tumor tissues were pretreatment speci-
mens, snap-frozen within 30 minutes of surgical removal. A
hematoxylin and eosin (H&E) stained section was cut from each
tumor specimen and reviewed by a pathologist to verify histology
and to delineate regions of tissue with a tumor cell content of
$70%. All specimens and accompanying clinicopathological
information were anonymized, and procured with appropriate
IRB approval. The Office of Human Subjects Research declared
exempt for human specimen usage because the specimens were
anonymized when investigators received them: The exemption
numbers are #3529, #3456, and #3534.
Identity Testing
To confirm that tumor-normal pairs were consistent with
derivation from the same individual, all human DNA samples
were genotyped using the Coriell Identity Mapping kit (Coriell).
Genotyping fragments were size separated on an ABI-3730xl DNA
analyzer (Applied Biosystems). Alleles were scored using Gene-
Mapper software.
Primer Design, PCR Amplification, and Nucleotide
Sequencing
Primer pairs to amplify ATAD5 were designed using published
methods [43] (Table S4). PCR products were subjected to
bidirectional Sanger sequencing using the BigDye Terminator
Version 3.1 Cycle Sequencing Kit (Applied Biosystems). Sequenc-
ing reactions were run on ABI 3730xl DNA Analyzers (Applied
Biosystems). Sequence data was analyzed as described in the
Supplemental Experimental Procedures.
Laser Capture Microdissection and RT-PCR
Pure populations of tumor cells were isolated from heteroge-
neous tissue sections by laser capture microdissection (LCM) using
an Arcturus PixCell IIe system. RT-PCR products, generated
from microdissected tumor cells were sequenced to discriminate
between monoallelic and biallelic expression of mutant ATAD5
alleles.
Analysis of Atad5
+/m ES Cells, MEFs, and Mice
The wild-type and mutant Atad5 alleles were distinguished by
PCR using primers: 1298NF (59- GAG ACT GTC TCA CCA
TGT ACA GGG-39), 1372NR (59- ATA AAT TGT AAA AAA
TCG ATC TCT-39) and pGKR (59- GTG GCC TGT CCC
TCT CAC CTT CTA-39). PCR products of 542 bp and 900 bp
distinguished the wild-type and mutant alleles, respectively
(Figure 1B). PCR conditions were an initial denaturation step at
94uC for 5 minutes, followed by 35 cycles of a denaturation step at
94uC for 30 seconds, an annealing step at 55uC for 30 seconds,
and an elongation step at 72uC for 60 seconds and by a final
elongation step at 72uC for 7 minutes. There were no additional
insertions of the retroviral vector in the genome of RRF055 ES
cells, as confirmed by Southern hybridization with a NEO probe.
The ES cells were injected to into C57BL/6 blastocytes that were
transferred into pseudopregnant CD1 female recipients. A
resulting chimeric male mouse was mated with C57BL/6 females.
Germline transmission was confirmed in progeny of agouti mice.
The germline transmitted heterozygous mice were crossed with
wild-type 129/Sv mice to increase the heterozygous population. In
addition, two heterozygous mice were mated to generate Atad5
m/m
mice. Mice were bred and maintained under a protocol (#G-05-
02) approved by the Institutional Animal Care and Use committee
in the NHGRI, US NIH Animal Care Facility. Young Atad5
+/m
mice did not show any distinct phenotypic features and were
fertile. However, when the Atad5
+/m mice were intercrossed, we
did not observe any postnatal progeny that were homozygous for
the Atad5 allele (Atad5
m/m).
Mouse embryonic fibroblast (MEF) cells were isolated from both
wild-type and Atad5
+/m embryos at day 13.5 p.c. and cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (high glucose, w/o
L-glutamine, w/o sodium pyruvate, GibcoBRL) supplemented
with 2 mM glutamine, 1% penicillin/streptomycin, 15% fetal calf
serum, 2 mM non essential amino acids, 0.1 mM 2-b mercapto-
ethanol in 4% oxygen concentration. RNAs isolated from wild-
type and Atad5
+/m MEFs were analyzed by RT-PCR with primer
sets specifically amplifying the region of mRNA containing exons 4
and 5, exons 18 and 19, or exons 19 and 20 respectively from
500 ng of total RNA isolated with TRIzol reagent (Invitrogen).
The expression of b-actin was used as an internal expression
control. For quantitative RT-PCR, reactions were performed
using the ABI7300 sequence Detection System (Applied Biosys-
tems) with an annealing temperature of 60uC and the following
primer pairs: Atad5-Ex4F (59-GAC TGA AGA AAC AGT GGT
ACC-39) and Atad5-Ex5R (59-CAA AGA CAG GAA TGG CTG
CTC-39); Atad5-Ex14F (59-GCC TCT TCA CAG CGA AGT
GG-39) and Atad5-Ex15R (59-GTG CTC GCT TCT GCC CAC
T-39); Atad5-Ex18F (59-GTC TAG TGT TTG ATG GCT GCT
TTG-39) and Atad5-Ex19R (59-CAC TTG TAG ATA GCT GGC
AAC-39); Atad5-Ex19F (59-GTT GCC AGC TAT CTA CAA
GTG-39) and Atad5-Ex20R (59-GAG CCA TCT TCT GAA CAA
ACC-39); and LacZR (59-CTT CGC TAT TAC GCCAGC
TGG-39).
Protein Analysis
Total cell extract was prepared by sonication of cells in lysis
buffer (100 mM Tris-Cl (pH 7.5), 50 mM NaCl, 8% glycerol, and
protease inhibitor cocktail (Roche) with either 0.5% Triton X-100
or 0.5% NP40 as a detergent). Supernatant after centrifugation
was used as total cell extract. Proteins in total cell extract were
separated by electrophoresis using 4–12% gradient polyacrylamide
gels (BioRad) and transferred to PVDF membranes (BioRad).
Proteins on PVDF membranes were detected by Western blotting
with antibodies. Atad5 protein was detected by anti ELG1
antibody raised in rabbits against human N-terminal 1–197 amino
acid fragments of ELG1. Fused Elg1 protein was detected by anti-
Beta galactosidase antibody (Abcam).
The TritonX-100-insoluble fraction (chromatin bound fraction)
was isolated from the Triton X-100-soluble fraction using the
traditional methods with slight modifications. Harvested cells were
resuspended in buffer A (100 mM NaCl, 300 mM sucrose, 3 mM
MgCl2, 10 mM Pipes (pH 6.8), 1 mM EGTA, 0.2% Triton X-
100, 100 mM NaVO4, 50 mM NaF, and protease inhibitors
(RocheApplied Science)) and incubated for 5 minutes on ice with
gentle inverting. The supernatants were recovered as the ‘‘soluble
fraction’’ after centrifugation. Followed by washing with buffer A,
the pellet was resuspended either in buffer X (100 mM Tris-HCl
(pH 8.5), 250 mM NaCl, 1 mM EDTA, 1% Nonidet P-40,
100 mM NaVO4, 50 mM NaF, 2 mg/ml bovine serum albumin,
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150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS,
100 mM 100 mM NaVO4, 50 mM NaF, and protease inhibitors)
for immunoblotting. Followed by a 10 min incubation on ice, the
samples were sonicated and then incubated for another 10 min on
ice before centrifugation to isolate the ‘‘chromatin-bound
fraction.’’ Immunoblots were stained with PCNA (Santa Cruz)
and Rad9 (Cell Signaling) antibodies.
Generation of Atad5
m/m Mouse Embryos
All embryos were generated by natural mating of Atad5
+/m mice.
The morning of the day on which a vaginal plug was detected was
designated as day 0.5 p.c. and 3.5 p.c. embryos were collected by
flushing uteri with M2 medium (Sigma). To genotype embryos
collected at other embryonic days, individual yolk sacs were lysed
in 20 ml of 1xPCR lysis buffer with 0.2 mg/ml of proteinase K at
55uC for overnight.
Chromosomal Abnormalities and Cell Survival Assay
MEFs were treated with the indicated doses of methyl methane
sulfonate (MMS) for 2 hours, washed with PBS three times, and
incubated in media for one day. Colcemid (0.1 mg/ml) was added
to the medium over night before cells were collected. For each cell
culture, 50 metaphases were analyzed for chromosomal abnor-
malities. MEFs were plated in 96 well plates (1,000 cells/well) in
triplicate. The following day, cells were treated with MMS at
different doses, ranging from 0.00012 to 0.01% for one hour. Cells
were washed with PBS and incubated for ten more days. Cell
survival was determined using the CyQuant cell proliferation assay
kit (Invitrogen).
Immunofluorescence and Confocal Microscopy
MEF cells were cultured in 2 well Lab Tek chamber slides
(Nunc) chamber slide. The next day cells were fixed with 3.7%
para-formaldehyde, treated with 0.2% tritonX-100 and stained
with phospho-H2AX (a-c-H2AX; Millipore) and Rad51 (Santa
Cruz) antibodies. Fluorescence conjugated anti IgG antibodies
(Invitrogen-Molecular Probes) were used as a secondary antibody.
Confocal images were collected with a Ziess LSM 510 NLO meta
system mounted on a Ziess Axiovert 200 M microscope with an oil
immersion Plan-Apochromat X 63/1.4 differential interference
contrast objective lens.
Sister Chromatid Exchange for MEF Cells
MEF cells cultured in 10 cm culture dish for one day were
incubated with BrdU for 36 hours. Cells were then treated
overnight with Colcemid (0.1 mg/ml). For each cell culture, 50
metaphases were analyzed for sister chromatid exchange abnor-
malities.
Cell Cycle Analysis for MEF Cells
MEF cells cultured in 10 cm culture dishes for a day were
harvested and washed three times with PBS. Following fixation
with 70% ethanol, cells were washed with PBS, stained with PI
solution, and kept at 37uC for 30 minutes before sorting. Data
were analyzed by ModFIT software (http://www.vsh.com/
products/mflt/index.asp).
Generation of the Heterozygous ATAD5-Deficient
Chicken DT40 Cells
The full-length chicken cDNA (DDBJ accession number
AB511312) encodes a protein of 1,816 amino acids with 45.6%
identity to human ATAD5. Partial chicken (ch) ATAD5 cDNA and
genomic sequences were identified by searching databases and
cloned by PCR. To knock out ATAD5 in chicken DT40 cells, a
chATAD5 targeting vector was designed to replace a region that is
homologous to the RFC large subunit, RFC1 (PRKO4195) as
assigned by conserved domain database with a drug-resistant gene
cassette (Figure S1A). The ATAD5-targeting vector was created by
replacing a 2.7 kb genomic fragment containing 3 exons that
correspond to chATAD5 amino acids 1338–1735, with a his-
resistant gene cassette. DT40 cell cultures, electroporation and
subsequent selection, RT-PCR analysis, cell growth determina-
tion, colony formation assay were performed as described [44–46].
For c-ray irradiation,
137Cs gammacell 40 exactor (MDS Nordion)
was used. One allele of chATAD5 gene was targeted as evidenced
by Southern blot (Figure S1B). Semi-quantitative RT-PCR
analysis showed that ATAD5 mRNA levels were decreased to
nearly half of the wild type level (Figure S2C). Despite numerous
attempts to disrupt the second allele, we were unable to recover
homozygous chATAD5 null DT40 cells. In striking contrast to the
targeting efficiency of the first chATAD5 allele ,10% (3/29), no
double positive clones were obtained from 139 transfectants. Thus,
we speculate that complete loss of the chATAD5 gene might be
lethal.
Pulsed-Field Gel Electrophoresis
MEFs were treated with 0.01% MMS for one hour and then
allowed to recover for 16 hours. ,6610
5 cells were imbedded into
Pulsed-Field Certified Agarose (Bio-Rad) for a final agarose
concentration of 0.75%. Agarose plugs were then digested in
proteinase K reaction buffer (100 mM EDTA, pH 8.0, 0.2%
sodium deoxycholate, 1% sodium lauryl sarcosine, and 1 mg/ml
Proteinase K) at 50uC overnight and washed 4 times in wash
buffer (20 mM Tris, pH 8.0, 50 mM EDTA). The plugs were
loaded onto a 1% Pulsed-Field Certified Agarose gel (Bio-Rad).
Separation was performed on a CHEF-DR III pulsed-field
electrophoresis system (Bio-Rad; 100u field angle, 1200 s switch
time, 2 V/cm, 14uC) for 72 hours. The gel was stained with
ethidium bromide.
Array-Based Comparative Genome Hybridization (CGH)
Analysis
Genomic DNA isolated from normal and tumor tissues from the
Atad5
m/+ mice, using the DNeasy Blood and Tissue Kit (Qiagen,
Valencia, CA), was used for array-CGH array analysis assisted by
the NHGRI Genomics core. Data analysis was performed by the
NHGRI Bioinformatics core. DNAs were hybridized to Whole
Mouse Genome CGH Microarrays (105K) (Agilent Technologies)
according to the manufacturer’s protocol. After hybridization,
arrays were washed and scanned. The scanned array images were
analyzed and data was extracted using Agilent Feature Extraction
(FE) Software with Linear Lowess normalization and background
subtraction. Agilent’s DNA Analytics Software (Version 4.0.85)
was used to identify chromosomal imbalances. The altered chro-
mosomal regions and breakpoints were detected using ADM-1
with threshold 6.0.
Tissue Microarray Analysis, Pathway Analysis, and
Integration of CGH Data with Expression Analysis
Expression profiling was accomplished using the Agilent High
Throughput Array (HTA) GeneChip system. All the necessary
enzymes and reagents were purchased from the SABiosciences
unless specified below. Total RNA was isolated from normal and
tumor tissues by guanidinium thiocyanate-phenol-chorofrom
extraction using TRIzol reagent (Invitrogen) following the
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and 2 tumor) samples were reverse transcribed into cDNA using
T7dT24 primer containing the poly T sequence and the promoter
for T7 RNA polymerase. After second strand synthesis, double-
stranded cDNA was used as a template to synthesize comple-
mentary RNA (cRNA) in a modified ‘‘Eberwine’’ type RNA
amplification process. During this amplification process, cRNA
was labeled with aminoallyl-UTP (Sigma). 8 mg of aminoallyl-
cRNA from each sample was conjugated with Cy3-NHS ester (GE
Healthcare) to generate Cy3-labelled cRNA. 1.65 mg Cy3-labelled
cRNA generated was fragmented by the cRNA fragmentation
reaction and then applied for hybridization. Hybridization was
done at 65uC for 17 hours with 4 rpm shaking. The Whole Mouse
Genome Oligo Microarray assembly was then dissembled in the
hybridization wash buffer 1 at room temperature. The microarray
slides were washed with the fresh hybridization wash buffer 1 for
1 minute, followed with the hybridization with the wash buffer 2 for
one minute at 37uC, with acetonitrile for 1 minute at room
temperature, and with the stabilization and drying solution for
30 seconds. The dried microarray slide was scanned into a TIFF
imagefileonanAgilentmicroarrayscannerat5 mmre so lu ti onus in g
default settings. Microarray intensity data were extracted from the
TIFF image using the Agilent Feature Extraction Software 9.1.3.
The Feature Extraction Softwarealsoprocessed the signal intensities
from Cy3 channel for each microarray. The processed data were
then imported into GeneSpring GX 10 (Agilent Technologies)
software and normalized using the standard settings for Agilent
microarray including per chip global normalization. Global
normalization was performed by dividing each measurement by
the 50
th percentile of all measurements in that sample. The
percentile was calculated using only genes marked as present. Data
for genes that were absent in all samples and all the control probes
were excluded from analyses. Paired t-test were performed to
identify a list of statistically significant (P,0.05) differentially
expressed genes between normal and tumor samples with a cut-off
criteria of expression differences greater than or equal to 2-fold.
Each differentially expressed gene was classified according to its
GeneOntology(GO),inwhichgenesareorganizedintohierarchical
categories based on biological process, molecular function and
cellular compartment. GO term analysis was performed using
Genespring GX 10 software. To determine the functional
relationships among the identified genes, differentially expressed
genes were imported into Ingenuity Pathway Analysis software (IPA)
(http://www.ingenuity.com). IPA contains the most literature
knowledge of biological interactions among the gene products. This
web-based software generated a set of molecular network based on
interaction between uploaded genes and all other genes present in
the knowledge base. In order to compare the measurements
obtained from CGH array analysis and microarray expression data,
the genes that were present in regions of amplification and deletion
detected by array-CGH were chosen to determine their correlation
in microarray expression. The goal of this analysis was to detect
genes where a copy number change is correlated with the change in
expression. Multiple public expression database, Oncomine
(https://www.oncomine.org/resource/login.html) was manually
interrogated for mouse Atad5 and its aliases. Only studies comparing
normal against tumor tissues were queried for this gene.
Nucleic Acid Isolation
Genomic DNA was isolated from macrodissected tissue with
greater than 70% tumor purity using the Puregene kit (Qiagen).
Total RNA was isolated with TRIzol (Invitrogen), according to the
manufacturer’s instructions. cDNA was synthesized using the
Super Script III First Strand Synthesis System (Invitrogen).
Human Cell Line Culture and Transfection
Human embryonic kidney (HEK) 293T cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS) (Hyclone), 100 U/mL penicillin G and
100 mg/mL streptomycin. Transfections were carried out using
Lipofectamine2000 (Invitrogen) and cells were incubated for 48 h
prior to harvesting. For RNA interference, transfection was
performed two times with an interval of 24 h.
DNA Constructs and siRNA
Full-length ATAD5 cDNA was cloned into p3XFLAG CMV10
expression vector and used as a template for site-directed
mutagenesis with the QuickChange Site-Directed Mutagenesis
kit (Stratagene). Construct integrity was verified by nucleotide
sequencing. siRNAs (Dharmacon) to target the 39 untranslated
region (Utr) of ATAD5 were: 59- GUAUAUUUCUCGAUGUAC
A-39 (sense) and 59- UGUACAUCGAGAAAUAUACUU -39
(antisense).
Immunoprecipitation and Immunoblotting
Triton X-100 soluble and insoluble fractions were isolated using
a modified version of the method described by Kannouche et al
[47]. For immunoprecipitation, proteins were pre-cleared with
protein G Sepharose beads (GE Healthcare), incubated with
specific antibodies, and then the complex recognized by antibodies
was precipitated with protein G Sepharose beads. Proteins or
immunoprecipitated samples were resolved on NuPAGE Novex
4–12% Bis-Tris Gel (Invitrogen) and transferred to PVDF
membranes (Bio-Rad), followed by immunoblotting.
Quantitative Reverse Transcription and Real-Time PCR
Total RNAs (500 ng), prepared using TRIzol (Invitrogen) were
subjected to qRT-PCR using the SuperScriptIII Platinum Two
Step qRT-PCR kit (Invitrogen) and a 7300 Real Time PCR system
(Applied Biosystems). Primer sequences used for qRT-PCR were:
ATAD5, 59-CGG AGA CGA AGA AAG CAA AG-39 (sense) and
59-CAA TGA GAA ACA AGG GCA GA-39 (antisense), b-actin,
59-GCT CGT CGT CGA CAA CGG CTC-39 (sense) and 59-CAA
ACA TGA TCT GGG TCA TCT TCT C-39 (antisense). b-actin
expression served as an internal control.
PCR Amplification of ATAD5 from Clinical Samples
PCR was performed in a total volume of 10 ml containing 5 ng
genomic DNA, 0.16 mM sense primer, 0.16 mM antisense primer,
and Immomix (Bioline). PCR amplification was performed on
MBS Satellite 384 Thermalcyclers (Thermo Scientific). Cycling
conditions were 95uC for 3 min followed by 40 cycles of 95uC for
15 s; 60uC for 15 s; 72uC, 1 min; followed by a final extension of
72uC for 5 min.
Nucleotide Sequencing of ATAD5 from Clinical Samples
Sequence trace quality was assessed with the base-calling
program, Phred [48–50]. All traces were included in the
subsequent analysis, since deletion-insertion polymorphisms can
mimic poor quality data from a Phred-quality measure, but may
contain valid sequence data. All sequences for a given primer pair
were assembled using Consed [50]; overlapping amplimers were
assembled separately to allow independent cross validation of calls
in overlapping regions. Sequence variants, including single-
nucleotide differences and short (,100 base pair) insertions and
deletions, were identified using PolyPhred v6.11 [51] and
DIPDetector, an insertion-deletion (indel) detector optimized for
improved sensitivity in finding insertions and deletions from
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produces traces that are superpositions of two alleles of different
length, DIPDetector is able to use Phred’s primary and secondary
peak predictions at each base position to calculate an autocorre-
lation function of the trace with itself shifted by different potential
insertion or deletion sizes. A maximum in the value of this function
with respect to shift size indicates a potential indel. To improve
accuracy, DIPDetector also examines the trace alignments for
homozygous insertions and deletions, and uses these homozygous
genotypes to refine its prediction for the insertion or deletion
position, resulting in greater accuracy of positions when compared
to PolyPhred. Human genome assembly hg18 (NCBI Build 36.1)
was used as the reference sequence. Variant positions were cross-
referenced to dbSNP (Build 129) entries to identify known
polymorphisms. To determine whether novel variants were somatic
mutations or germline polymorphisms, the appropriate tumor DNA
and matched normal DNA were re-amplified in an independent
PCR followed by sequence analysis of the variant position.
Laser Capture Microdissection and RT-PCR
Frozen tissue sections (8 mM) of OCT-embedded primary
tumors were prepared at American HistoLabs Inc., (Gaithersburg
MD), and were H&E stained immediately prior to microdissection.
Approximately 4000–5000 laser pulses were performed using the
following infrared laser parameters: laser spot size 7.5 mm, power
70 mW, duration 950 ms. Each tissue section and the subsequent
dissection was reviewed by a staff pathologist. RNA was isolated
from LCM samples using the Arcturus Picopure RNA isolation kit
(MDS Analytical Technologies). RNA (50–200 ng) was converted
to cDNA using SuperScript III First-Strand Synthesis System
(Invitrogen). RT-PCR primers were designed to span intronic
boundaries to avoid amplification of any contaminating genomic
DNA. Primer sequences (59-39) were: CTT TTT GAG GAG
GTT GAT G (sense) and GTC CAA GTC AGT GTC AAA
TAG ATC AC (antisense). Purified RT-PCR products were
subjected to bidirectional sequencing to determine whether there
was monoallelic or biallelic expression of mutant ATAD5 alleles.
Supporting Information
Figure S1 Establishment of heterozygous ATAD5-deficient
chicken DT40 cells by targeted disruption. (A) Schematic
representation of part of the chicken (ch) ATAD5 locus, the gene
targeting constructs, and the configuration of the targeted allele.
The black box indicates the position of exons. B, BamHI site. (B)
Southern blot analysis of BamHI-digested genomic DNA from
DT40 cells of the indicated genotypes, using a flanking probe as
shown in panel A. (C) Semi-quantitative RT-PCR analysis of
ATAD5 mRNA expression. cDNAs prepared from wild-type and
two heterozygous cells (Clones 1 and 2) were serially diluted and
subjected to PCR amplification using primers shown as open
triangles in panel A. The gel picture is shown in the left panel. N,
no cDNA template. GAPDH was also amplified as control.
Densitometric analysis of ATAD5 band intensity was carried out
using Image J software and plotted in the right panel. (D) Survival
of DT40 cells of the indicated genotypes was evaluated by colony
survival in medium containing methylcellulose after exposure to
increasing doses of c-irradiation. Error bars indicate the standard
deviation from at least three experiments. (E) Survival of chicken
DT40 cells with indicated genotypes was evaluated by colony
survival in medium containing methylcellurose by continuous
exposure to different doses of MMS. Error bars indicate standard
deviation from at least three experiments. * and ** indicate
statistical significance of p,0.05 and p,0.01, respectively by the
Student’s t-test. (F) Chromosome analysis of DT40 cells with the
indicated genotypes. Cells were c-ray irradiated (+, 2Gy) or left
untreated (2, 0 Gy) and sampled at indicated time points. One
hundred metaphases were scored blindly for each preparation as
described [44]. Error bars indicated standard deviations.
FANCD2 deficient DT40 cells were used as a control [52].
(TIF)
Figure S2 MEFs derived from the Atad5
+/m mice have molecular
defects in suppression of PCNA ubiquitination. The level of PCNA
ubiquitination in response to 0.01% MMS treatment was
compared between wild-type and Atad5
+/m MEFs. Bottom table
shows the levels of PCNA and Ubiquitinated PCNA (Ub-PCNA)
quantified by comparing to Histone H3. The level of Ub-PCNA
quantified by comparing to PCNA is in the same table.
(TIF)
Figure S3 Differential mRNA expression in tumors from
Atad5
+/m mice. (A) Results of unsupervised hierarchical clustering
of two tumors from Atad5
+/m animals. Red indicates increased
gene expression and green indicates decreased gene expression in
tumors (two right hand columns) relative to controls provided by
surrounding tissues (two left hand columns). (B, C) Quantitative
RT-PCR analysis confirmed the expression changes for (B) four
genes that exhibited increased expression by microarray analysis
and (C) three genes that exhibited decreased expression by
microarray analysis.
(TIF)
Figure S4 The ATAD5-R1414X somatic mutation is heterozy-
gous in endometrial tumor T51. (A) Sequence trace of matched
germline DNA surrounding ATAD5 codon 1414 (boxed). Only the
wild type sequence is detectable. (B) Sequence trace of genomic
PCR products generated from macrodissected tumor tissue from
T51. Both wildtype and mutant bases are detected at codon 1414
(arrow). (C) Sequence trace of RT-PCR products generated from
pure populations of tumor cells obtained by laser capture
microdissection of tumor T51. Both wildtype and mutant bases
are detected at codon 1414 (arrow).
(TIF)
Table S1 Regions of copy number alteration and the corre-
sponding genes among four tumors from Atad5
+/m mice.
(PDF)
Table S2 List of cancer gene transcripts that had up or down
regulated expression in two tumor samples compared to their
normal controls.
(PDF)
Table S3 Genes that showed both altered expression and copy
number in murine tumors.
(PDF)
Table S4 Primers used to PCR amplify human ATAD5.
(TIF)
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